Bladder cancer relapse and treatment failure in most patients have often been attributed to chemoresistance in tumor cells and metastasis. Emerging evidence indicates that tumor heterogeneity may play an equally important role and extends to virtually all measurable properties of cancer cells. Although the idea of tumor heterogeneity is not new, little attention has been paid to applying it to understand and control bladder cancer progression. With the development of biotechnology, such as Gene sequencing, recent advances in understanding its generation model, original basis, consequent problems, and derived therapies provide great potential for tumor heterogeneity to be considered a new insight in the treatment of bladder cancers.

Keywords:
Tumor heterogeneity, Bladder cancer, Personalized medicine, Therapy
1.
Mitra AP, Cote RJ: Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol 2009;4:251-285.
2.
Berger I, Martini T, Wehrberger C, et al: Perioperative complications and 90-day mortality of radical cystectomy in the elderly (75+): a retrospective, multicentre study. Urol Int 2014;93:296-302.
3.
Kunath F, Krause SF, Wullich B, et al: Bladder cancer - the neglected tumor: a descriptive analysis of publications referenced in MEDLINE and data from the register ClinicalTrials.gov. BMC Urol 2013;13:56.
4.
Knowles MA: Molecular pathogenesis of bladder cancer. Int J Clin Oncol 2008;13:287-297.
5.
Yap TA, Gerlinger M, Futreal PA, et al: Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012;4:127ps10.
6.
Fidler IJ: Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 1978;38:2651-2660.
7.
Foulds L: Tumor progression. Cancer Res 1957;17:355-356.
8.
Heppner GH, Miller BE: Tumor heterogeneity: biological implications and therapeutic consequences. Cancer Metastasis Rev 1983;2:5-23.
9.
Woodruff MF: Cellular heterogeneity in tumours. Br J Cancer 1983;47:589-594.
10.
Baldus SE, Schaefer KL, Engers R, et al: Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010;16:790-799.
11.
Ding L, et al: Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010;464:999-1005.
12.
Ding L, et al: Clonal evolution in relapsed acute myeloid leukemia revealed by whole-genome sequencing. Nature 2012;481:506-510.
13.
Shah SP, et al: Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009;461:809-813.
14.
Nik-Zainal S, et al: The life history of 21 breast cancers. Cell 2012;149:994-1007.
15.
Campbell PJ, Yachida S, et al: The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010;467:1109-1113.
16.
Stephens PJ, et al: Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011;144:27-40.
17.
Durrett R, Foo J, Leder K, et al: Intratumor heterogeneity in evolutionary models of tumor progression. Genetics 2011;188:461-477.
18.
Bjerkvig R, Tysnes BB, Aboody KS, et al: Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer 2005;5:899-904.
19.
Tysnes BB, Bjerkvig R: Cancer initiation and progression: involvement of stem cells and the microenvironment. Biochim Biophys Acta 2007;1775:283-297.
20.
Polyak K, Hahn WC: Roots and stems: stem cells in cancer. Nat Med 2006;12:296-300.
21.
Miller SJ, Lavker RM, Sun TT: Interpreting epithelial cancer biology in the context of stem cells: tumor properties and therapeutic implications. Biochim Biophys Acta 2005;1756:25-52.
22.
Ojha R, Jha V, Singh SK, et al: Autophagy inhibition suppresses the tumorigenic potential of cancer stem cell enriched side population in bladder cancer. Biochim Biophys Acta 2014;1842:2073-2086.
23.
Nishizawa S, Hirohashi Y, Torigoe T, et al: HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells. Cancer Res 2012;72:2844-2854.
24.
Yin B, Zeng Y, Liu G, et al: MAGE-A3 is highly expressed in a cancer stem cell-like side population of bladder cancer cells. Int J Clin Exp Pathol 2014;7:2934-2941.
25.
Campbell LL, Polyak K: Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle 2007;6:2332-2338.
26.
Li Y, Xu X, Song L, et al: Single-cell sequencing analysis characterizes common and cell-lineage-specific mutations in a muscle-invasive bladder cancer. Gigascience 2012;1:12.
27.
Gui T, Cao D, Yang J, et al: Tumor heterogeneity has important consequences for personalized medicine in ovarian cancer. Histol Histopathol 2014, Epub ahead of print.
28.
Badve S, Nakshatri H: Breast-cancer stem cells-beyond semantics. Lancet Oncol 2012;13:e43-e48.
29.
Landau DA, et al: Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013;152:714-726.
30.
Greaves M, Maley CC: Clonal evolution in cancer. Nature 2012;481:306-313.
31.
Cahill DP, Kinzler KW, Vogelstein B, et al: Genetic instability and darwinian selection in tumours. Trends Cell Biol 1999;9:M57-M60.
32.
Markowitz S, et al: Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336-1338.
33.
Lee AJ, et al: Chromosomal instability confers intrinsic multidrug resistance. Cancer Res 2011;71:1858-1870.
34.
Alexandrov LB, et al: Signatures of mutational processes in human cancer. Nature 2013;500:415-421.
35.
Sieber OM, et al: Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 2003;348:791-799.
36.
Burrell RA, McGranahan N, Bartek J, et al: The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013;501:338-345.
37.
Sauter G, Moch H, Moore D, et al: Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res 1993;53:2199-2203.
38.
Iyer G, Al-Ahmadie H, et al: Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol 2013;31:3133-3140.
39.
Cazier JB, Rao SR, et al: Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden. Nat Commun 2014;5:3756.
40.
Hasegawa R, Fujiwara K, Obinata D, et al: Identification of frequent differentially methylated region in sporadic bladder cancers. Urol Int 2014, Epub ahead of print.
41.
Junttila MR, de Sauvage FJ: Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013;501:346-354.
42.
Orimo A, et al: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121:335-348.
43.
Polanska UM, Orimo A: Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. J Cell Physiol 2013;228:1651-1657.
44.
Quante M, et al: Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011;19:257-272.
45.
Kalluri R: Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003;3:422-433.
46.
Trédan O, Galmarini CM, Patel K, et al: Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007;99:1441-1454.
47.
Fridman WH, Pagès F, Sautès-Fridman C, et al: The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12:298-306.
48.
Brown TM, Fee E: Rudolf Carl Virchow: medical scientist, social reformer, role model. Am J Public Health 2006;96:2104-2105.
49.
Keats JJ, Chesi M, Egan JB, et al: Clonal competition with alternating dominance in multiple myeloma. Blood 2012;120:1067-1076.
50.
Chen RJ, Ho YS, Guo HR, et al: Long-term nicotine exposure-induced chemoresistance is mediated by activation of Stat3 and downregulation of ERK1/2 via nAChR and beta-adrenoceptors in human bladder cancer cells. Toxicol Sci 2010;115:118-130.
51.
Sanaee MN, Malekzadeh M, Khezri A, et al: Soluble CD138/syndecan-1 increases in the sera of patients with moderately differentiated bladder cancer. Urol Int 2014, Epub ahead of print.
52.
Cooke SL, Ng CK, Melnyk N, et al: Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene 2010;29:4905-4913.
53.
Meads MB, Gatenby RA, et al: Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009;9:665-674.
54.
Rosland GV, Engelsen AS: Novel points of attack for targeted cancer therapy. Basic Clin Pharmacol Toxicol 2015;116:9-18.
55.
Konishi N, Hiasa Y, Matsuda H, et al: Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. Am J Pathol 1995;147:1112-1122.
56.
Esrig D, Spruck CH 3rd, et al: p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143:1389-1397.
57.
Xue W, Zender L, Miething C, et al: Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007;445:656-660.
58.
Chabner BA, Roberts TG Jr: Timeline: chemotherapy and the war on cancer. Nat Rev Cancer 2005;5:65-72.
59.
Kim JJ, Tannock IF: Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 2005;5:516-525.
60.
Gatenby RA, Silva AS, Gillies RJ, et al: Adaptive therapy. Cancer Res 2009;69:4894-4903.
61.
Topalian SL, Weiner GJ, Pardoll DM: Cancer immunotherapy comes of age. J Clin Oncol 2011;29:4828-4836.
62.
Miller BE, Miller FR, Leith J, et al: Growth interaction in vivo between tumor subpopulations derived from a single mouse mammary tumor. Cancer Res 1980;40:3977-3981.
63.
Xu X, Hou Y, Yin X, et al: Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 2012;148:886-895.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.